ENVIRI CORPORATION

RESTRICTED STOCK UNITS AGREEMENT

(FORM - TIME-BASED VESTING)

This RESTRICTED STOCK UNITS AGREEMENT (this “Agreement”) is made as of [●] (the “Date of Grant”), by and between Enviri Corporation, a Delaware corporation, and [PARTICIPANT NAME] (the “Participant”).

1.    Certain Definitions. Capitalized terms used, but not otherwise defined, in this Agreement will have the meanings given to such terms in the Company’s 2026 Omnibus Incentive Plan (as amended from time to time, the “Plan”).

…

SIXTH AMENDMENT TO INDUSTRIAL LEASE

This SIXTH Amendment to Industrial Lease (the “Sixth Amendment”) is made and entered into as of July 31, 2026, by and among GSNTR ATX 1200 BMC DRIVE OWNER LP, a Delaware limited partnership (“Building 1 Owner”), GSNTR ATX 1202 BMC DRIVE OWNER LP, a Delaware limited partnership (“Building 2 Owner”) (Building 1 Owner and Building 2 Owner are collectively referred to herein as “Landlord”), and HYLIION INC., a Delaware corporation (“Tenant”).

RECITALS:

…

SECOND AMENDMENT TO FLOOR PLAN FACILITY AGREEMENT

    THIS SECOND AMENDMENT TO FLOOR PLAN FACILITY AGREEMENT (this“Amendment”) is made effective as of May 15, 2026 (the “Amendment Date”), among RUMBLEON DEALERS, INC., a Delaware corporation (the “Borrower”), RIDENOW GROUP, INC. (f/k/a RumbleOn, Inc.), a Nevada corporation (“Holdings”), WILLIAM R. COULTER (“Coulter”), MARK A. TKACH (“Tkach” and, together with Coulter, the “Lenders”), and RIDENOW MANAGEMENT LLLP, an Arizona limited liability limited partnership, as Administrative Agent (the “Administrative Agent).

RECITALS

WHEREAS, the Borrower, Holdings, the Lenders and the Administrative Agent are parties to that certain Floor Plan Facility Agreement dated as of December 6, 2024 (the “Floor Plan Facility Agreement”) and that certain First Amendment to Floor Plan Facility Agreement dated as of August 25, 2025 (the “First Amendment”), which collectively, and as amended hereby, constitute the “Amended Floor Plan Facility Agreement”.

…

Exhibit 10.9*

Neuronetics, Inc.

2026 Equity Incentive Plan

Adopted by the Board of Directors: March 18, 2026

Approved by the Stockholders: May 28, 2026

1.General.

(a)Successor to and Continuation of Prior Plan. This 2026 Equity Incentive Plan (the “Plan”) is intended as the successor to and continuation of the Company’s 2018 Equity Incentive Plan (the “Prior Plan”). From and after 12:01 a.m. Eastern Time on the date the Plan is approved by the Company’s stockholders (the “Stockholders”; such time and date, the “Stockholder Approval Date”), no additional awards will be granted under the Prior Plan. All awards granted on or after the Stockholder Approval Date will be granted under the Plan. All awards granted under the Prior Plan will remain subject to the terms of the Prior Plan. All awards granted under the Company’s Amended and Restated 2003 Stock Incentive Plan will remain subject to the terms of that plan.

…

AMENDMENT NO. 4 TO THE

INHIBIKASE THERAPEUTICS, INC.

2020 EQUITY INCENTIVE PLAN

The Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan (as amended, the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Inhibikase Therapeutics, Inc. (the “Company”), but subject to approval by the Company’s stockholders in accordance with Section 11 of the Plan:

1. Section 3(a) of the Plan is amended and restated in its entirety as follows:

…

Inhibikase therapeutics, INC.
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The purpose of this Non-Employee Director Compensation Policy (as may be amended from time to time, the “Policy”) of Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”). This Policy will become effective as of the date of its adoption, as written below (the “Effective Date”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as Outside Directors as set forth below:

Cash Retainers

…

****SolidEnergy Systems LLC

35 Cabot Road, Woburn, MA 01801

​

​

April 20, 2026

​

Jing Nealis

2050 Harvest Road

Pleasanton, CA 94566

​

RE: Separation Agreement

​

Dear Jing:

​

This agreement will confirm the terms of your separation from employment with SolidEnergy Systems, LLC (the “Company”).

​

1.Separation of Employment**.  **Your last date of employment with the Company will be April 27, 2026 (the “Separation Date”).  From and after the Separation Date, you shall have no authority and shall not represent yourself as an employee or agent of the Company and/or its predecessors, successors, past or present subsidiaries, affiliated companies, investors, branches or related entities. You further agree to be available to provide assistance and transitional services to your successor as Chief Financial Officer upon reasonable request to support his or her transition into the role through May 15, 2026.

​

…

‌Beyond Li-ion™

SolidEnergy Systems LLC

35 Cabot Road, Woburn, MA 01801

​

Yi (Ray) LiuApril 8, 2026
512 Wyoming Avenue

Millburn, NJ

​

Re:Employment as Chief Financial Officer

​

​

Dear Ray:

​

Welcome to SES! I am pleased to confirm the terms on which you will be employed by SolidEnergy Systems LLC (the “Company”).

​

| | |

…

LENZ THERAPEUTICS, INC.

OUTSIDE DIRECTOR COMPENSATION POLICY

LENZ Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside Directors”). This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding cash compensation and grants of equity awards to its Outside Directors. Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company’s 2024 Equity Incentive Plan, as amended from time to time (or if such plan no longer is in use at the time of the grant of an equity award, the meaning given such term or any similar term in the equity plan then in place under which such equity award is granted) (such applicable plan, the “Plan”). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director a

…

May 11, 2026

Dr. Pedro Beltran

Re: Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement

Dear Pedro:

This agreement confirms the terms of your employment as Chief Executive Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Amended and Restated Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Employment Agreement, dated August 11, 2025, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

May 11, 2026

Idan Elmelech

Re: Employment Agreement and Executive Severance Plan Participation Agreement

Dear Idan:

This agreement confirms the terms of your employment as Chief Operating Officer of the Company commencing as of the Effective Date (as defined below). If executed, this Employment Agreement and Executive Severance Plan Participation Agreement (the “Agreement”) shall become effective retroactively as of April 20, 2026 (the “Effective Date”). Except with respect to the Equity Documents, the Restrictive Covenants Agreement (as defined below) and the Severance Plan (each as defined below), this Agreement supersedes in all respects all prior agreements between you and BridgeBio Oncology Therapeutics, Inc. (the “Company”) (or its predecessor(s)) regarding the subject matter herein, including without limitation (i) the Offer Letter, dated April 16, 2024, by and between you and the Company (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.

1.

…

AMENDMENT NO. 9

TO TRANSITION SERVICES AGREEMENT

This Amendment No. 9 (“Amendment No. 9”) to the Agreement (as defined below) is entered into as of June 23, 2026 (the “Effective Date”) by and among BridgeBio Services Inc., a Delaware corporation (“BBIO”), TheRas, Inc., a Delaware corporation (“BBOT”), BridgeBio Pharma LLC (“BBP LLC”), and BridgeBio Oncology Therapeutics, Inc. (“PubCo”). BBIO, BBOT, BBP LLC and PubCo may be referred to herein by name or individually, as a “Party” and collectively, as the “Parties.” Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement (as defined below) to the extent defined therein.

WHEREAS, BBIO and BBOT entered into that certain Transition Services Agreement, dated April 30, 2024, as amended (the “Agreement”);

WHEREAS, the Parties now wish to further amend the Agreement to update the Service Schedule on Exhibit A thereto;

…